Trials / Not Yet Recruiting
Not Yet RecruitingNCT06109402
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice. However, it is unclear whether therapeutic strategy is superior. This trial aims to compare the efficacy and safety of these two strategies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Nab-paclitaxel | Specified dose on specified days |
| PROCEDURE | Surgery | Surgery for II-IIIB (N2) non-small cell lung cancer |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2030-11-01
- Completion
- 2030-11-01
- First posted
- 2023-10-31
- Last updated
- 2023-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06109402. Inclusion in this directory is not an endorsement.